Creagan E T, Ahmann D L, Schutt A J, Green S J
Cancer Treat Rep. 1982 Jun;66(6):1425-6.
Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU). Sixteen patients had received prior systemic therapy, and 16 had visceral involvement. There were no objective regressions among ten patients receiving the drugs as initial systemic therapy. However, one of 16 patients having prior systemic treatment did have an objective response. Hematologic and gastrointestinal toxic effects were well-tolerated.
26例播散性恶性黑色素瘤患者接受了米托萘醇和司莫司汀（甲环亚硝脲）的口服治疗方案。16例患者此前接受过全身治疗，16例有内脏受累。在10例接受该药物作为初始全身治疗的患者中未出现客观缓解。然而，在16例此前接受过全身治疗的患者中，有1例出现了客观反应。血液学和胃肠道毒性反应耐受性良好。
